| To: BiotaBull who wrote (251) | 3/14/2005 11:09:15 PM | | From: Tadsamillionaire | | | | GenoMed, Inc. Says New Medicare Legislation May Accelerate Acceptance of Its Therapy
ST LOUIS, March 10 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News) said today that recently adopted legislation allowing pharmacists to take an expanded role in providing healthcare could accelerate acceptance of the company's treatment protocol for a number of diseases.The company said the adoption by Congress of the Medicare Modernization Act allows a pharmacist, under a doctor's supervision, to help manage patients' medications. It provides compensation to the pharmacists for services such as checking blood pressure and adjusting blood pressure medication.
"This is potentially an important development for GenoMed," said GenoMed CEO and chief medical officer David W. Moskowitz. "One of the obstacles to the broad acceptance of our treatment protocol has been the difficulty patients encounter in obtaining appointments with their physician. In the startup phase of our protocol, relatively frequent appointments are needed to take blood pressure and adjust the drug dosage of ACE inhibitor, which is the core of our treatment. That has been difficult because physicians are so busy that seeing them every two weeks is often impossible. Now that the difficulty of adopting our treatment can be easier, patients may be more willing to enroll."
"Our patent-pending protocols to arrest or prevent diabetes, high blood pressure and other diseases are ideal for the nation's 55,000 retail pharmacists. They can work closely with physicians and GenoMed while seeing patients with the frequency needed to gather and provide the necessary data to titrate the dosage. Since under the new law pharmacists are able to receive compensation for services like taking blood pressure and adjusting medication, they should be willing to participate," Moskowitz said.
Moskowitz, speaking earlier this week at the 28th annual conference of the National Council of Prescription Drug Plans said GenoMed's data has demonstrated that ACE inhibitors can prevent kidney failure in patients with diabetes or high blood pressure. ACE inhibitors are a commonly prescribed drug that, as their name implies, inhibits the action of the ACE gene. GenoMed's research has identified ACE as a "master disease gene" linked to the development of a large number of common diseases.
Moskowitz noted that other speakers at the conference agreed that prescription drugs are the best value in health care. Properly used, they can eliminate hospitalization, which is far more expensive. They can also prevent the onset of many diseases that, once contracted, require ongoing and expensive treatment.
Several of the large Pharmacy Benefit Management organizations represented at the conference expressed an interest in the GenoMed protocol because it employs drugs that are available in generic form. These organizations have been strong advocates of the use of generic drugs to help control healthcare costs.
"We believe the Medicare Modernization Act provides us with an opportunity to accelerate the acceptance of our protocol. The interest expressed by various entities in using GenoMed's treatment, combined with the economic incentives now available to retail pharmacists make it easier for patients to participate. We are actively pursuing this opportunity and are encouraged by the more favorable environment," Moskowitz said.
biz.yahoo.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 3/24/2005 5:15:30 PM | | | | | | GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter; Says GenoMed Set to Improve Nation's Public Health
March 24, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its Chairman and CEO, Dr. David Moskowitz, is featured in Wall Street Reporter Magazine discussing how preventive molecular medicine as GenoMed practices it can significantly lower healthcare costs.
wallstreetreporter.com
GenoMed also participated in a recent Genomics Roundtable hosted by the Wall Street Reporter Magazine, available at:
wallstreetreporter.com
GenoMed has aligned its business model with optimizing public health. The Company's goal is to find the least expensive, fastest, and safest way to improve patient outcomes. The Company has already accomplished this for diabetes, hypertension, and emphysema, which affect over 85 million Americans. This summer GenoMed will again conduct a free national trial for West Nile virus using already existing, FDA-approved drugs.
GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account to sign up themselves for GenoMed's modestly priced services.
About GenoMed
GenoMed has already found what it believes is the major gene for aging. Using this information, GenoMed has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics, dramatically delay the progression of terminal emphysema, and treat autoimmune diseases and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic and therapeutic tools ready for clincal trials soon.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 4/6/2005 4:23:26 AM | | | | | | GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care
Contact: Dr. David Moskowitz
GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com
April 5, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced that its Chairman and CEO, Dr. David Moskowitz, has been invited to speak today at The 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care.
This conference, held outside Washington, DC (http://www.worldcongress.com/wcls/ccd/index.cfm) presents the nation's best practices and thought leaders in implementing successful disease management programs that produce positive clinical and financial outcomes. The conference agenda was designed to address the market demands from employers and public purchasers as well as the leading edge programs offered by health care insurers and providers. The agenda highlights legislative trends that impact the adoption and scope of disease management programs including updates from the Centers for Medicaid and Medicare (CMS) on its Chronic Care Improvement Program.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've been invited to this inaugural conference because our business model consists of using genomics to improve public health, and we've been uniquely successful at it so far for diabetes, hypertension, and emphysema, which together affect over 85 million Americans."
Continued Dr. Moskowitz, "GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account or who can afford $67 a month out-of-pocket to sign up themselves for GenoMed's services."
About GenoMed
GenoMed has found what it believes to be the major gene for aging, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see treatment successes for autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic tools ready for clincal trials soon, with new cancer chemotherapy to follow.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 4/20/2005 11:42:42 AM | | | | | | GenoMed Completes First Version of Healthchip(r) for Cancer Prediction
Contact: David Moskowitz MD tel. 314-983-9933 GenoMed, Inc.
ST. LOUIS, April 20, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has constructed a Healthchip® which may serve as an early warning system for the top six common cancers in whites: breast, colon, lung, ovarian, pancreatic, and prostate.
GenoMed's Healthchip® is made up of many single nucleotide polymorphisms (SNPs). In internal testing, the Healthchip® correctly identified the type of cancer in 85% of cases. None of the normals were misdiagnosed. More testing is required to confirm these results.
The well known breast cancer genes, BRCA1 and BRCA2, account for only 5% of breast cancers in white women. GenoMed's SNPs may pick up the remaining 95% of sporadic breast cancer cases in white women, i.e. in women without a strong family history of breast cancer.
Said Dr. David Moskowitz, GenoMed's chairman and chief executive officer, "It's important for any screening test to have as few false positives as possible. GenoMed's Healthchip® currently has none."
The test for mutations in the BRCA1 and BRCA2 genes costs about $1,200, has been available for about a decade, and has been reimbursed by a handful of insurance plans for the past few years. GenoMed's test is currently available for research purposes only, and is not yet reimbursable by any health plan. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com to inquire about GenoMed's testing program.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 5/5/2005 2:25:49 PM | | | | | | GenoMed CEO Invited to Speak at Harvard Medical School 25th Class Symposium
Contact: David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(May 5, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to speak on Clinical Genomics at the 25th Class Symposium at Harvard Medical School on June 9, 2005 (http://134.174.17.106/alumni/program-05.pdf
Said Dr. Moskowitz, "It's a tremendous honor to be selected to speak at our 25th medical class reunion. Since publishing three years ago that angiotensin I-converting enzyme ('ACE') might be the aging gene, I've been trying hard to get the word out. Last week at 'World DNA and Genome Day' in Dalian, China, the reception was quite enthusiastic. Speaking at Harvard next month should be equally productive. I've already gotten inquiries from Harvard Medical School alumni who've seen the Class Day program. The point of my talk will be that all physicians should be practicing clinical genomics already."
Added Dr. Moskowitz, "GenoMed's primary goal right now is to educate the 80 million American Baby Boomers and their physicians, not to mention the rest of the world, that medicine has already been revolutionized. Unfortunately, an entire cohort of kidney patients is just now going on dialysis in the U.S. because their physicians didn't hear about our published results three years ago. If we'd gotten to these patients then, we could have kept them off the kidney machine now. Getting the word out to patients and their physicians in time is absolutely critical. Disease doesn't wait."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. Disease Management (DM) is the only business in healthcare which profits by lowering healthcare costs. GenoMed uses clinical genomics to keep patients healthier and out of the hospital. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that GenoMed applied for patents based on its finding that the ACE gene is associated with many common diseases.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (257) | 5/7/2005 8:41:25 AM | | From: Tadsamillionaire | | | | Dr M's Thoughts about the roomers of a Gmed buyout:
Dear ,
There's no way we'd sell out cheaply, not when each wild
card patent would be worth two years of a $3 billion a year drug. We may have the makings of 20 or 30 of these wild card patents. Do the math: $3B/yr x 2 yr/wild-card x 30 wild-card patents = $180 B.
We'd also have to retain full operational control over our Next Generation DM(tm) activities in any acquisition.
So if we get acquired, it won't be cheap. My goal remains to be huge ourselves. I just wanted people to have
some idea of the magnitude of what we might be sitting on, since (a) preventing kidney dialysis, (b) significantly delaying emphysema, (c) finding the aging gene for all vertebrate species, (d) being able to predict which Caucasians will get which of the top six solid cancers, (e)
having a potential broad-spectrum anti-viral treatment, (f) having a SNPnet which can efficiently find predisposition genes for all cancers in all ethnic groups, and (g) inventing a business model that finally makes preventive medicine profitable, have evidently not been enough to be
valued by the market at more than 6 cents a share.
All I can say is, talk about a tough audience! Enron, etc. did more than just destroy consumer confidence. Those boys destroyed trust in any company. Then again, maybe our problem is just lack of publicity. I continue to think
that 80 million Baby Boomers might appreciate knowing about (c), at the very least. Unless they still think they're going to live forever, as we
did in 1968.
Yours sincerely,
Dave Moskowitz MD
ragingbull.lycos.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (259) | 5/26/2005 8:18:07 PM | | From: Tadsamillionaire | | | | Growing concern over a persistent epidemic of bird flu across Asia is leading to urgent calls from international scientists to prepare for a global flu pandemic that could strike, by some estimates, 20% of the world's population. In a collection of articles published Thursday in the journal Nature, scientists sketch out a scenario in which a strain of bird flu, which usually would not be dangerous to people, adapts to become highly contagious and deadly to humans.
news.yahoo.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 5/26/2005 8:21:00 PM | | | | | | Avian influenza – cumulative number of cases – update 18
19 May 2005
WHO is updating its table showing cumulative numbers of human cases of H5N1 avian influenza broken down according to phases in the outbreak, which began in December 2003. [Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO]. Numbers for Viet Nam, where the vast majority of recent cases have occurred, have been amended in line with case counts provided by the Ministry of Health during late April and May. Since the third wave of infection began in Viet Nam in mid-December 2004, 49 cases have been reported. Of these cases, 17 were fatal. The most recent case was reported to the ministry on 17 April.
WHO has asked the Ministry of Health in Viet Nam to supplement the numbers with data on individual cases. Rapid field investigation of new cases, especially when these occur in clusters, remains essential to assess possible changes in transmission patterns that could indicate improved pandemic potential of the virus.
Since January 2004, when human cases of H5N1 avian influenza were first reported in the current outbreak, 97 cases and 53 deaths have been reported in Viet Nam, Thailand and Cambodia. Viet Nam, with 76 cases and 37 deaths, has been the most severely affected country, followed by Thailand, with 17 cases and 12 deaths, and Cambodia, with 4 cases and 4 deaths.
who.int
U.S. unprepared against new flu -experts The United States still has no licensed vaccine to prevent avian flu and has nowhere near enough drugs to treat the sick if there is an epidemic, experts told Congress on Thursday.
Hospitals have too little capacity to deal with the huge numbers of people who would become sick and the U.S. Health and Human Services Department does not have a plan for dealing with an epidemic, the experts said.
"Although many levels of government are paying increased attention to the problem, the United States remains woefully unprepared for an influenza pandemic that could kill millions of Americans," said Dr. Andrew Pavia, chairman of the Infectious Disease Society of America's Pandemic Influenza Task Force.
"Clearly, we need a much larger supply of drugs and vaccine to control a flu pandemic. We need to build up U.S. manufacturing capacity so that we are not dependent on other countries to meet our needs," Pavia said in remarks prepared for a hearing of the health subcommittee of the House of Representatives' Energy and Commerce Committee.
Dr. Julie Gerberding, director of the U.S. Centers for Disease Control and Prevention, said the government was working hard to address the threat.
"CDC's influenza budget is $197 million ... a lot larger than just a few years ago," Gerberding said. "We have a lot of work to do, and that work needs to be a priority."
The H5N1 strain of avian flu has killed 37 people in Vietnam, 12 in Thailand and four in Cambodia.
It could sicken up to 20 percent of the world's population if it acquires the ability to pass easily among people, says influenza expert Dr. Albert Osterhaus of the Erasmus Medical Center in Rotterdam, Netherlands.
A pandemic could send 30 million people to the hospital and a quarter of them could die, Osterhaus and colleagues predicted in articles in Thursday's issue of the journal Nature.
Influenza causes epidemics annually and kills 36,000 Americans in a normal season. Different strains emerge almost annually, and a new one can kill many more if it is one that has not affected people in recent years.
A brand-new strain, such as H5N1, could be devastating.
"The U.S. population has no immunity and therefore no protection against this deadly virus," Pavia said.
He recommended that the United States stockpile a larger supply of antiviral drugs, especially oseltamivir, made by Switzerland's Roche under the brand name Tamiflu. Avian influenza resists older antiviral drugs, like amantadine and rimantadine, but Tamiflu can help make an infection less severe.
Although Roche has quadrupled its production capacity for Tamiflu, experts believe global stockpiles will be too small for a pandemic. The current stockpile would treat less than 2 percent of the U.S. population. Pavia's group recommends having enough on hand to treat 50 percent.
The U.S. government has also contracted with Sanofi-Aventis and Chiron Corp. to make H5N1 flu vaccines, but the contracts provide for only 2 million doses and the vaccines are still experimental.
The U.S. Government Accountability Office also criticized the U.S. lack of preparation.
Marcia Crosse, Director of Health Care for the GAO, said in prepared testimony that the United States needs to address regulatory, privacy, and procedural issues surrounding measures to control the spread of disease, especially across borders.
news.yahoo.com
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
